Mouse IgG1 isotype control [15H6]
Cat# GTX35014-100μg
Size : 100μg
Brand : GeneTex
Host | Mouse |
---|---|
Clonality | Monoclonal |
Clone Name | 15H6 |
Isotype | IgG1 |
Application | WB, ICC/IF, IHC-P, IHC-Fr, FACS, IP, ELISA, in vitro, in vivo |
Package | 100 μg |
View product citations for antibody GTX35014 on CiteAb
APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application | Recommended Dilution |
---|---|
WB | Assay dependent |
ICC/IF | Assay dependent |
IHC-P | Assay dependent |
IHC-Fr | Assay dependent |
FACS | Assay dependent |
IP | Assay dependent |
ELISA | Assay dependent |
in vitro | Assay dependent |
in vivo | Assay dependent |
Not tested in other applications.
Product Note
T-2 mycotoxin
PROPERTIES
Form
Liquid
Buffer
Borate buffered saline
Preservative
No preservative
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Immunogen
T-2 mycotoxin
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
Mouse IgG1 negative control , Mouse IgG1 isotype control , Mouse isotype control for IgG1 kappa , Negative control for Mouse IgG1 kappa , Mouse IgG1 kappa negative control , Mo , monoclonal Mouse IgG1 isotype control , Isotype control for Mouse IgG1 kappa
Background
Inclusion of an appropriate isotype control is essential for the proper interpretation of experimental results. Because isotype control antibodies have no relevant specificity, they enable the researcher to distinguish non-specific "background" binding from antigen-specific antibody binding. Non-specific binding of primary antibodies may occur due to either binding of antibody to Fc receptors or non-specific interactions with cellular proteins, lipids, or carbohydrates. Additionally, autofluorescence or endogenous enzyme activity in target cells may give a false positive that could be misinterpreted as antibody binding. These factors vary by target cell type and the isotype of the primary antibody. Therefore, the primary antibody used should be matched to an isotype control of identical species and isotype (including both heavy and light chains).
Application Reference
?rtykov ?? et al. Cancers (Basel) 2020; 12 (5) Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B more Efficiently than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors.
Yagolovich AV et al. Transl Oncol 2020; 13 (4) : 100762 Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile.
Sheen YS et al. J Pathol 2020; 250 (4) : 452-463 Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1-mediated increase in vascular permeability.
Lee MH et al. J Leukoc Biol 2019; 106 (4) : 967-975 The cytokine network type I IFN-IL-27-IL-10 is augmented in murine and human lupus.
Clone Reference
Chopra H et al. Blood Cells Mol Dis 2021; 86:102487 CD133+CD34+ cells can give rise to EPCs: A comparative rabbit and human study.
Submit a Reference REVIEW
Application Reference
?rtykov ?? et al. Cancers (Basel) 2020; 12 (5) Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B more Efficiently than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors.
Yagolovich AV et al. Transl Oncol 2020; 13 (4):100762 Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile.
Sheen YS et al. J Pathol 2020; 250 (4):452-463 Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1-mediated increase in vascular permeability.
Lee MH et al. J Leukoc Biol 2019; 106 (4):967-975 The cytokine network type I IFN-IL-27-IL-10 is augmented in murine and human lupus.
Zaharieva I et al. Hum Mutat 2018; (Epub) STAC3 variants cause a congenital myopathy with distinctive dysmorphic features and malignant hyperthermia susceptibility.
Benson BL et al. Sci Rep 2018; 8 (1):9328 Biomimetic post-capillary venule expansions for leukocyte adhesion studies.
Vukcevic M et al. J Cell Sci 2013; 126 (Pt 15):3485-92 Gain of function in the immune system caused by a ryanodine receptor 1 mutation.
Clone Reference
Chopra H et al. Blood Cells Mol Dis 2021; 86:102487 CD133+CD34+ cells can give rise to EPCs: A comparative rabbit and human study.
You might also be interested by the following products:
Cat#
Description
Cond.
Price Bef. VAT